These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 8657690)

  • 1. [Evaluation of clinical significance of tuberculin sensitization in patients with lung cancer].
    Knoring BE; Ariél' BM
    Probl Tuberk; 1996; (2):26-30. PubMed ID: 8657690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tuberculin sensitization in patients with lung cancer].
    Knoring BE; Arièl' BM
    Vopr Onkol; 1994; 40(7-12):288-93. PubMed ID: 7610622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cutaneous reactions to tuberculin in cancer patients. Prognostic value].
    Israël L; Mawas C; Bouvrain A; Sors MC
    Bull Mem Soc Med Hop Paris; 1967 Mar; 118(5):469-76. PubMed ID: 6075134
    [No Abstract]   [Full Text] [Related]  

  • 4. [Diagnostic value of the tuberculin skin test as a parameter of cellular immunocompetence in cancer patients].
    Sone S; Ogushi F; Tsubura H; Fukuoka M
    Kekkaku; 1983 Oct; 58(10):559-62. PubMed ID: 6319794
    [No Abstract]   [Full Text] [Related]  

  • 5. [Immune response in patients with lung cancer].
    Mar'in ND; Kupin VI; Kadagidze ZG
    Vopr Onkol; 1979; 25(12):72-3. PubMed ID: 516588
    [No Abstract]   [Full Text] [Related]  

  • 6. [Delayed hypersensitivity response of the skin to 2,4-dinitrochlorobenzene and old tuberculin in patients with lung cancer].
    Fan XJ
    Zhonghua Zhong Liu Za Zhi; 1983 Sep; 5(5):333-6. PubMed ID: 6653356
    [No Abstract]   [Full Text] [Related]  

  • 7. Cell-mediated immunity in lung cancer patients: data, problems, and propositions.
    Israel L
    Cancer Chemother Rep 3; 1973 Mar; 4(2):279-81. PubMed ID: 4729330
    [No Abstract]   [Full Text] [Related]  

  • 8. [On the tuberculin susceptibility of lung cancer patients (author's transl)].
    Jensen I
    Offentl Gesundheitswes; 1980 Jun; 42(6):311-3. PubMed ID: 6448374
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-survivin antibody responses in lung cancer.
    Karanikas V; Khalil S; Kerenidi T; Gourgoulianis KI; Germenis AE
    Cancer Lett; 2009 Sep; 282(2):159-66. PubMed ID: 19380192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Contribution to the study of phenomena of cellular immunity in pulmonary cancer before palliative or surgical treatment].
    Israel L; Bouvrain A; Cros-Decam J; Mugica J
    Poumon Coeur; 1968; 24(3):339-50. PubMed ID: 5726401
    [No Abstract]   [Full Text] [Related]  

  • 11. [Symposium on cancer and immunity. (3) Diagnostic immunological parameter in cancer patients (author's transl)].
    Yata K
    Nihon Naika Gakkai Zasshi; 1978 Dec; 67(12):1495-9. PubMed ID: 744891
    [No Abstract]   [Full Text] [Related]  

  • 12. [Immunological state of patients with malignant tumor of the bronchi and lung examined by PPD test (author's transl)].
    Grbac I; Basić-Grbac M; Jakasa D; Mulhim M
    Plucne Bolesti Tuberk; 1978; 30(4):324-8. PubMed ID: 752820
    [No Abstract]   [Full Text] [Related]  

  • 13. Cellular and humoral immunity to purified protein derivative (PPD) in PPD skin reactive and nonreactive patients with pulmonary tuberculosis: comparative analysis of antigen-specific lymphocyte proliferation and IgG antibodies.
    Boras Z; Juretić A; Rudolf M; Uzarević B; Trescec A
    Croat Med J; 2002 Jun; 43(3):301-5. PubMed ID: 12035136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung cancer.
    Strieter RM; Belperio JA; Burdick MD; Sharma S; Dubinett SM; Keane MP
    Ann N Y Acad Sci; 2004 Dec; 1028():351-60. PubMed ID: 15650260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunomorphology of lung cancer].
    Dikshtein EA; Kurennaia SS
    Vopr Onkol; 1981; 27(1):102-4. PubMed ID: 7456435
    [No Abstract]   [Full Text] [Related]  

  • 16. The complement system in tumor immunity: significance of elevated levels of complement in tumor bearing hosts.
    Nishioka K; Kawamura K; Hirayama T; Kawashima T; Shimada K
    Ann N Y Acad Sci; 1976; 276():303-15. PubMed ID: 1071966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
    Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
    Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
    Pan QR; Zhang X; Xu ZF; Zheng S
    Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective elimination of lung metastases induced by tumor cells treated with hydrostatic pressure and N-acetyl-L-cysteine.
    Goldman Y; Peled A; Shinitzky M
    Cancer Res; 2000 Jan; 60(2):350-8. PubMed ID: 10667587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for occult nodal metastasis in clinical T1N0 lung cancer: a negative impact on survival.
    Veeramachaneni NK; Battafarano RJ; Meyers BF; Zoole JB; Patterson GA
    Eur J Cardiothorac Surg; 2008 Mar; 33(3):466-9. PubMed ID: 18249130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.